Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21421680 | 0.98 | FFAR1 (0.51) | FFAR1USP30PRMT5WDR77DGAT1 | |
| SCHEMBL21405360 | 0.98 | FFAR1 (0.51) | FFAR1USP30PRMT5WDR77DGAT1 | |
| SCHEMBL18551339 | 0.93 | FFAR1 (0.50) | FFAR1USP30PRMT5WDR77DGAT1 | |
| SCHEMBL24540152 | 0.89 | FFAR1 (0.51) | FFAR1USP30PRMT5WDR77DGAT1 | |
| SCHEMBL21421693 | 0.89 | FFAR1 (0.48) | FFAR1USP30PRMT5WDR77DGAT1 | |
| SCHEMBL1725558 | 0.86 | FFAR1 (0.57) | FFAR1USP30PRMT5WDR77DGAT1 | |
| SCHEMBL25291902 | 0.84 | FFAR1 (0.50) | FFAR1USP30PRMT5WDR77DGAT1 | |
| SCHEMBL844227 | 0.83 | FFAR1 (0.60) | FFAR1USP30PRMT5WDR77DGAT1 | |
| SCHEMBL18530455 | 0.83 | FFAR1 (0.54) | FFAR1USP30PRMT5WDR77DGAT1 | |
| SCHEMBL25248137 | 0.82 | FFAR1 (0.53) | FFAR1USP30PRMT5WDR77DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| EP-4452978-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023115150-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115150-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | FFAR1 1395/4885USP30 1167/4885PRMT5 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.